Literature DB >> 30989332

Discordance between doctor and patient assessments and non-adherence to subcutaneous biological drugs.

Teresa Otón1, Loreto Carmona2, Ana Urruticoechea-Arana3, Jaime Calvo-Alén4, Maria J Arteaga5, Luis Cea-Calvo5.   

Abstract

To estimate the agreement level between patient and physician assessment of disease activity and to explore whether agreement is associated with adherence to subcutaneous (SC) biological drugs in rheumatoid arthritis (RA). Cross-sectional study of RA patients who had been prescribed a SC biological drug in the past 12-18 months was performed. Patients and physicians global disease activity on visual analogue scale (VAS) were collected. Disagreement was defined as an absolute difference ≥ 3 points between VAS scores. Adherence was assessed by the Medication Possession Ratio (MPR), considering adherence an MPR > 80%. We analysed 360 patients of whom 15.5% presented disagreement with their physicians. The mean patient global VAS was 5.75 ± 1.8 (median 5.5 [5-7]) in the disagreement group versus 2.7 ± 2.2 (median 2 [1-4]) in the agreement group (p < 0.001). There were also differences in physicians global VAS between groups (p = 0.01). The non-adherence to SC biological drugs rate was 10.7% and 14.5% in the disagreement and agreement groups (p = 0.45). No association between adherence and discordance was found. Disagreement in the global disease activity between patients and physicians was detected in 15.5% of patients. In general, patients perceived higher disease activity. No associations between patient-physician disagreement in VAS and adherence were observed.

Entities:  

Keywords:  Adherence; Biological drugs; Compliance; Discordance; Disease activity; Patient perspective

Mesh:

Substances:

Year:  2019        PMID: 30989332     DOI: 10.1007/s00296-019-04304-w

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  15 in total

Review 1.  Adherence to HAART among patients with HIV: breakthroughs and barriers.

Authors:  J R Ickovics; C S Meade
Journal:  AIDS Care       Date:  2002-06

Review 2.  Adherence to medication.

Authors:  Lars Osterberg; Terrence Blaschke
Journal:  N Engl J Med       Date:  2005-08-04       Impact factor: 91.245

Review 3.  Factors associated with adherence to pharmaceutical treatment for rheumatoid arthritis patients: a systematic review.

Authors:  Annelieke Pasma; Adriaan van't Spijker; Johanna M W Hazes; Jan J V Busschbach; Jolanda J Luime
Journal:  Semin Arthritis Rheum       Date:  2013-01-24       Impact factor: 5.532

Review 4.  [Thinking differently the patient medication compliance: from an injunctive posture to a working alliance between the patient and the healthcare provider: concepts and determinants].

Authors:  M Baudrant-Boga; A Lehmann; B Allenet
Journal:  Ann Pharm Fr       Date:  2011-11-25

5.  Non-adherence to subcutaneous biological medication in patients with rheumatoid arthritis: a multicentre, non-interventional study.

Authors:  Jaime Calvo-Alén; Indalecio Monteagudo; Georgina Salvador; Tomás R Vázquez-Rodríguez; Juan V Tovar-Beltrán; Paloma Vela; Francisco Maceiras; Sagrario Bustabad; José A Román-Ivorra; Consuelo Díaz-Miguel; José Rosas; Enrique Raya; Loreto Carmona; Luis Cea-Calvo; María J Arteaga; Sabela Fernández; Carlos Marras
Journal:  Clin Exp Rheumatol       Date:  2016-12-28       Impact factor: 4.473

6.  Assessment of rheumatoid arthritis patients' adherence to treatment.

Authors:  Mohsen A Gadallah; Dina N K Boulos; Asmaa Gebrel; Sahar Dewedar; Donald E Morisky
Journal:  Am J Med Sci       Date:  2015-02       Impact factor: 2.378

7.  Determinants of discordance between patients and physicians in their assessment of lupus disease activity.

Authors:  Jim C Yen; Michal Abrahamowicz; Patricia L Dobkin; Ann E Clarke; Renaldo N Battista; Paul R Fortin
Journal:  J Rheumatol       Date:  2003-09       Impact factor: 4.666

8.  The Challenge of Assessing Adherence to Subcutaneous Biological Drugs in Immune-Mediated Inflammatory Diseases. Letter to the Editor Regarding Michetti P, Weinman J, Mrowietz U, et al. Adv Ther (2017);34:91-108. doi:10.1007/s12325-016-0441-3.

Authors:  Luis Cea-Calvo; Loreto Carmona; Jaime Calvo-Alén
Journal:  Adv Ther       Date:  2017-08-17       Impact factor: 3.845

9.  Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database.

Authors:  Peter Bhoi; Louis Bessette; Mary J Bell; Cathy Tkaczyk; Francois Nantel; Karina Maslova
Journal:  BMJ Open       Date:  2017-09-18       Impact factor: 2.692

10.  Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability.

Authors:  Virginia Pascual-Ramos; Irazú Contreras-Yáñez; Antonio R Villa; Javier Cabiedes; Marina Rull-Gabayet
Journal:  Arthritis Res Ther       Date:  2009-02-19       Impact factor: 5.156

View more
  1 in total

Review 1.  Physician Adherence to Treat-to-Target and Practice Guidelines in Rheumatoid Arthritis.

Authors:  Bogdan Batko; Krzysztof Batko; Marcin Krzanowski; Zbigniew Żuber
Journal:  J Clin Med       Date:  2019-09-08       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.